top of page

Tue, May 19



Webinar | Watchman | Left Atrial Appendage closure device

Coming soon | A one-time procedure that may reduce stroke risk for a lifetime in people with AFib not caused by a heart valve problem.

Registration is Closed
See other events
Webinar | Watchman | Left Atrial Appendage closure device

Time & Location

May 19, 2020, 5:00 PM PDT



About the Event

In 30 minutes, learn about the Watchman procedure, an innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a lifetime of warfarin use.

In patients with non-valvular atrial fibrillation (NVAF), more than 90% of stroke-causing clots that come from the left atrium form in the left atrial appendage (LAA). 3 WATCHMAN closes off the LAA, preventing blood clots from migrating out of it. The procedure is performed under general anesthesia in a catheterization laboratory using a standard percutaneous technique. This minimally invasive procedure usually lasts about an hour and patients typically stay in the hospital for a day. Following the procedure, patients typically take warfarin and aspirin for 45 days or until there is adequate seal. After discontinuing warfarin, patients take clopidogrel and an increased dose of aspirin, followed by ongoing aspirin therapy. 

Register to this Webinar, and discover the benefits of this procedure with Dr. Niraj Parekh, Interventional Cardiologist at CSMG. 

Dr. Parekh, Interventional Cardiologist at Cardiology Specialists medical Group, Director of Cardiac Cath Lab, and Director of Structural Heart  Interventions  and Transcatheter Valve Program

at Loma Linda Medical Center Murrieta 

After his Internal Medicine residency at UC San Diego, Dr. Parekh completed his General and Interventional Cardiology fellowships at Loyola University in Chicago. He specializes in percutaneous interventions of the coronary arteries as well as non-surgical technique to repair structural heart diseases. His expertise in vascular disease also allows him to treat peripheral arterial/venous disease including non-healing ulcers and wounds of the lower extremities, abdominal aortic aneurysms, and stenosis of the carotid vessels. He is committed to treating cardiovascular disease with minimally invasive procedures that allow faster recovery and improve patient care. 

bottom of page